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Abstract
Arachidonic acid is an unsaturated fatty acid liberated from phospholipids of cell membranes.
NSAIDs are known as targets of cyclooxygenase enzyme (COX-1, COX-2 and COX-3) in
arachidonic acid metabolism. This mechanism of COX-2 in carcinogenesis causes cancer. In
addition, COX-2 plays a role in the early stages of hepatocarcinogenesis. Hepatitis C virus (HCV)
infection is cause of liver cirrhosis and hepatocellular carcinoma (HCC). The aim of our study
was to improve effective agents against HCV. A novel series of new etodolac 1,2,4-triazoles
derivatives (4a–h) have been synthesized and investigated for their activity against HCV NS5B
polymerase. Compound 4a was found to be the most active with IC50 value of 14.8 mM. In
accordance with these results, compound 4a was screened for anti-cancer activity on liver
cancer cell lines (Huh7, Mahlavu, HepG2, FOCUS). Compound 4a showed anti-cancer activity
against Huh7 human hepatoma cell line with IC50 value of 4.29 mM. Therefore, compound 4a
could be considered as a new anti-cancer and anti-HCV lead compound.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) have recently
gained attention as promising cancer chemopreventive agents.
Evidence for a connection between COX-2 activation and
carcinogenesis has come from a number of studies1. In addition,
many epidemiological studies have also highlighted COX-2 as an
important molecular target for anti-cancer therapy.
Overexpression of COX-2 in tumor cell lines affect diverse
mechanisms involved in carcinogenesis, such as angiogenesis,
inhibition of apoptosis, stimulation of cell growth as well as the
invasiveness of tumor cells. Hepatocellular carcinoma (HCC) is
one of the most common cancers worldwide, accounting for
approximately 1 million deaths annually and an estimated 500 000
new cases per year2. Most cases of HCC are secondary to either
viral hepatitis infection (hepatitis B or C) or cirrhosis3. High
levels of COX-2 expression in hepatocytes may be involved in
hepatocarcinogenesis following HBV and HCV infections. COX-2
upregulation has also been correlated with the presence of
inflammatory cells in hepatocarcinogenesis and tumor angiogen-
esis in HCC4. COX-2 inhibitors have displayed significant anti-
proliferative effects in many human HCC cell lines5. Further,
investigations on animal models of liver cancer have shown that
NSAIDs, including selective COX-2 inhibitors, exhibit chemo-
preventive as well as therapeutic effects. Etodolac, (R,S)-2-[1,8-
diethyl-1,3,4-tetrahydrapyrano[3,4-b]indole-1-yl]acetic acid, is a
nonsteroidal antiinflammatory drug with marked antirheumatic,
analgesic and antipyretic properties. It exists as a racemic mixture
of R- and S-enantiomers that are not metabolically interconvert-
ible, of which the the S-enantiomer exhibits selective COX-2
inhibitory activity6. Etodolac, at physiological doses has been
reported to decrease the cell proliferative effect of b-catenin in
hepatoma cells7 and also decrease PGE2 levels in HCV-associated
HCC8. Other studies have reported the anti-HCC properties of
etodolac through mechanisms involving growth inhibition and cell
cycle arrest9. Thus, etodolac appears to be a promising scaffold
for the development of novel anti-hepatitis C and anti-HCC
agents.
Among other anti-tumor and anti-HCVagents, the 1,2,4-
triazoles and pyrano[3,4-b]indoles bearing compounds have dis-
played promising characteristics. The five-membered heterocyclic
ring of the triazoles has served as an important scaffold for many
bioactive compounds, some of which have emerged as effective
and non-toxic antitumor drugs10,11. The pyrano[3,4-b]indole
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derivatives, on the other hand, have been documented as
potent in vitro anti-HCV NS5B polymerase inhibitor12,13.
We recently reported on the synthesis of etodolac thiosemicar-
bazides and identified their anti-HCV NS5B polymerase
activity14.
In continuation of our efforts towards developing new anti-
cancer agents with enhanced biological properties and potent anti-
HCV NS5B polymerase activity, here we report on the synthesis
and biological evaluation of novel etodolac 1,2,4-triazole deriva-
tives. A total of 34 etodolac hydrazide derivatives were
investigated for their activity against HCV NS5B polymerase.
Selected compounds were evaluated for anti-cancer activity
against a panel of 60 human tumor cell lines in addition to four
hepatocellular cell lines We further report on the potential binding





All chemicals were purchased from Merck Co. (Darmstadt,
Germany), Sigma-Aldrich (St. Louis, MO) or Fluka (Buchs,
Switzerland). Reactions were monitored by thin-layer chroma-
tography (TLC) on aluminium oxide 60F254 plates (Merck Co.,
Darmstadt, Germany). Melting points of the synthesized com-
pounds were determined in Schmelzpunktgerät SMP II melting
point apparatus and are presented without any corrections. The
purity of the compounds was checked on TLC plates precoated
with silica gel G in a solvent system comprising of petroleum
ether: ethyl acetate (50:50, v/v) mixture as an eluent. The spots
were located under UV light (254 nm) (t: 21C). FT-IR spectra
were recorded on Shimadzu FTIR-8400S spectrophotometer.
NMR spectra were recorded on BRUKER AVANCE-DPX 400
at 400 MHz and Bruker 300 at 300 MHz (Billerica, MA) for 1H-
NMR and 75 MHz for 13C-NMR (Decoupled). The chemical
shifts () were expressed in parts per million (ppm) downfield
from tetramethylsilane (TMS) using DMSO-d6 as solvent. Data
are reported as follows: chemical shift, multiplicity (b.s.: broad
singlet, d: dublet; m: multiplet, s: singlet, and t: triplet),
coupling constants (Hz), integration. MALDI-TOF HR-MS
spectra using EI and FAB ionization techniques were performed
using a Jeol JMS-700 instrument.
Synthesis of methyl (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-
b]indole-1-yl) acetate 1, 2-(1,8-diethyl-1,3,4,9-tetrahydropyr-
ano[3,4-b]indole-1-yl)acetohydrazide 2, and 1-[2-(1,8-diethyl-
1,3,4,9-tetrahydropyrano[3,4-b]indole-1-yl)acetyl]-4-alkyl/aryl
thiosemicarbazides (3a-h)
These etodolac derivatives were designed and prepared as
described previously in our studies14–16.
General procedure for the synthesis 5-[(1,8-diethyl-1,3,4,9-
tetrahydropyrano[3,4-b]indole-1-yl)methyl]-4-substituted-2,4-
dihydro-3H-1,2,4-triazole-3-thiones (4a–h)
A solution of 0.01 mol (3a–h) in sodium hydroxide solution
(25 mL) was heated under reflux for 4 h. After cooling to room
temperature, the solution was adjusted to pH 6 by concentrated
hydrochloric acid. The crude product was precipitated, filtered
and washed with distilled water. Pure compounds were obtained
by recrystallization from ethanol.
The following compounds were prepared by an analogous
procedure. The characterization of compounds 4b–e, 4g–h could
be seen in Supplemental file 1.
5-[(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-yl)
methyl]-4-methyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
(4a). Light cream-colored solid. Yield 71%; m.p. 227–229C;
MW: 356.485; Rf 100 value: 46.77. FT-IR (max, cm1): 3279
(indole and triazole NH); 1562, 1470, 1464, 1456 (C¼N, C¼C);
1239 (C¼S). 1H NMR (400 MHz, DMSO-d6)  ppm: 0.64 (t, 3H,
–CH2–CH3 at C1); 1.27 (t, 3H, –CH2–CH3 at C8); 1.67–2.09 (m,
2H, –CH2–CH3 at C1); 2.57–2.89 (m, 4H, –CH2 at C1 and –CH2–
CH3 at C8); 3.30–3.46 (m, 5H, –CH2 at C4 and N–CH3); 3.85–
3.97 (m, 2H,–CH2 at C3); 6.89–7.24 (m, 3H, Ar-H); 10.67 (s, 1H,
indole NH); 13.49 (s, 1H, triazole NH). 13C NMR (100 MHz,
DMSO-d6/TMS)  ppm: 8.15 (C-12); 15.02 (C-10); 22.32 (C-4);
24.26 (C-9); 31.13 (C-11); 31.48 (N-CH3); 34.09 (C-13); 60.85
(C-3); 77.10 (C-1); 108.50 (C-5); 115.94 (C-1a); 119.26 (C-6);
120.30 (C-7); 126.32 (C-8a); 127.14 (C-8); 135.11 (C-5a); 135.63
(C-4a); 150.04 (triazol –C¼N); 169.90 (C¼S). HR-MS (EI+)
Calculated/Found (m/z): 356.1670/356.1663 (M+)
(C19H24N4OS); 324.1950/324.1943 (C19H24N4O); 281.1581/
281.1633; 279.1372/279.1453; 268.1576/268.1513; 243.1623/




(4f). Light cream-colored solid. Yield 50%; m.p. 163–166C;
MW: 432.581; Rf100 value: 80.60. FT-IR (max, cm1): 3270
(indole and triazole NH); 1574, 1497, 1453, 1418 (C¼N, C¼C);
1261 (C¼S). 1H NMR (400 MHz, DMSO-d6)  ppm: 0.67 (t, 3H,
–CH2–CH3 at C1); 1.26 (t, 3H, –CH2–CH3 at C8); 1.81–2.05 (m,
2H, –CH2–CH3 at C1); 2.82–3.35 (m, 6H, –CH2–CH3 at C8,
–CH2– at C1 and –CH2 at C4); 3.60-3.88 (m, 2H, –CH2 at C3);
5.21–5.32 (m, 2H, N–CH2); 6.89–7.36 (m, 8H, Ar-H); 10.62 (s,
1H, indole NH); 13.67 (s, 1H, triazole NH). 13C NMR (100 MHz,
DMSO-d6/TMS)  ppm: 8.18 (C-12); 14.94 (C-10); 22.26 (C-4);
24.24 (C-9); 31.39 (C-11); 34.35 (C-13); 46.22 (N–CH2); 60.89
(C-3); 77.13 (C-1); 108.37 (C-5); 115.99 (C-1a); 119.28 (C-6);
120.31 (C-7); 126.28 (C40); 127.11 (C20 and C60); 128.05 (C30
and C50); 129.15 (C-8 and C-8a); 135.09 (C-5a); 135.53 (C-
4a); 136.32 (C10); 149.64 (triazol –C¼N); 167.46 (C¼S).





Compounds 4b and 4f were chosen as prototypes for anti-cancer
evaluations at the National Institute of Health-National Cancer
Institute (NIH-NCI). Growth inhibition was evaluated against a
panel of 60 human tumor cell lines derived from nine neoplastic
diseases (leukaemia, non-small cell lung cancer (NSCL), colon
cancer, central nervous system (CNS) cancer, melanoma, ovarian
cancer, renal cancer, prostate cancer and breast cancer cell lines)
at 10-fold dilutionsin a primary anti-cancer assay in accordance
with the protocol of the Drug Evaluation Branch, NCI,
Bethesda17–19.
Briefly, the tumor cell lines were seeded in 96-well microtiter
plates in RPMI 1640 medium containing 5% fetal bovine serum
and 2 mM L-glutamine at 37 C, 5% CO2, 95% air and 100%
relative humidity atmosphere for 24 h19. Compounds were
screened at a single concentration of 105 M for 48 h and
growth inhibition was investigated by the sulforhodamine B
(SRB) protein assay17. The 50% inhibition was extrapolated from
dose–response parameters at 10-fold dilutions of compounds as
described previously18. The percentage of growth inhibition was































determined spectrophotometrically against DMSO treated
controls.
HCV NS5B polymerase inhibitory activity
The effect of the compounds on HCV NS5B polymerase activity
was evaluated on poly rA-U12 template- primer in the presence of
[a-32P] UTP and MnCl2 as the divlent cation as described
previously20,21. Reactions in the presence of the compound or
DMSO were incubated at 30 C for 1 h and terminated by the
addition of 5% TCA. The nascent radiolabeled RNA was
precipitated on GF-B filters and counted in a liquid scintillation
counter. NS5B activity in the presence of DMSO was set at 100%
and that in the presence of the compounds was determined
relative to this control. Preliminary screning was conducted at
100mM compound concetration and those exhibiting 50%
inhibition were investigated further for their IC50 values at 8-10
concentrations of the serially diluted compounds. The IC50 values
were analyzed from dose-response curves utilizing Graphpad
prism 3.03 software (La Jolla, CA).
Molecular modeling
The X-ray co-crystal structure of HCV NS5B-PF868554 (PDB
ID: 3FRZ) obtained from the RCSB Protein Data Bank
(Piscataway, NJ) was used for docking the compounds into the
NS5B thumb pocket-II22. The protein structure was processed by
means of default parameters mentioned in Protein Preparation
Tool present in Maestro v9.0 and Impact program v5.5
(Schrödinger, Inc., New York, NY), in which the protonation
states of residues were adjusted to the dominant ionic forms at pH
7.4. Refined HCV NS5B structure was further used to generate
energy grid by selecting bound inhibitor (PF868554) as a
reference ligand.
Docking protocol
Compounds were constructed using the fragment dictionary of
Maestro 9.0 and energy minimized by Macromodel program v9.7
(Schrödinger, Inc., New York, NY). The energy minimization
involved steepest descent followed by truncated Newton conju-
gate gradient application of OPLSAA force field parameters
(convergence criteria of 0.001 rmsd was used). The low-energy
3D structures of etodolac analogs were generated with the help of
LigPrep v2.3 (Schrödinger Inc., New York, NY): different
protonation states at physiological pH, all possible tautomers,
ring conformations and stereoisomers23. The resulting LigPrep
derived structures were used for docking simulations. The X-ray
co-crystal structure of HCV NS5B-PF868554 (PDB ID: 3FRZ)
was used for docking into thumb pocket-II22. Protein refinement
without crystallographic water molecules, energy grid generation
using bound ligand as a reference, and ‘‘Extra Precision’’ (XP)
Glide docking v5.0 (Schrödinger, Inc., New York, NY) was
performed with the default parameters. The top scoring pose of
compound 4a within the TP-II was used for graphical analysis. All
computations were carried out on a Dell Precision 470 n dual
processor with the Linux OS (Red Hat Enterprise WS 4.0,
Raleigh, NC).
NCI-Sulforhodamine B (SRB) anti-cancer assay of etodolac
triazole, SGK-238 on human liver cancer cells
Human liver cancer cells (Huh7, Mahlavu, HepG2, FOCUS) were
cultured in 96-well plates (1000–3000 cell/well) and grown for
24 h. Then the cells were treated with increasing concentrations of
the compound (2.5–40mM). After 72 h treatment, the growth
medium was aspirated and cells were washed with 1PBS
(CaCl2-, MgCl2-free) (Gibco, Invitrogen, Grand Island, NY)
followed by the addition of 50 ml cold 10% (v/v) trichloroacetic
acid (TCA) and incubated 1 h at 4C. TCA solution was then
aspirated and the micro-plates were washed five times with
deionized water and left air-dry. Finally, 50 ml of 0.4% (m/v)
sulforhodamine (Sigma-Aldrich) in 1% acetic acid solution was
added to each well and the plates were incubated for 10 min at
room temperature. In order to remove the unbound stain, the
plates were washed five times with 1% acetic acid and left to air-
dry. The bound sulforhodamine B was then solubilized using




cetic acid (etodolac) was chosen as the starting compound to
design 1,2,4-triazole-3-thiones derivatives. Synthesis of triazole
derivatives (4a–h) required stepwise reactions starting with
etodolac hydrazide. The synthetic route for the title compounds
is shown in Figure 1. In our previous study, we synthesized
methyl 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-yl)
acetate (1) and 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-
b]indole-1-yl)acetohydrazide (2)15. The reaction of corresponding
hydrazide 2 with respective alkyl/aryl isothiocyanates yielded
etodolac thiosemicarbazides (3a–h)14,16. In present study, smooth
cyclization of etodolac thiosemicarbazides under alkaline condi-
tions afforded the 5-[(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]
indole-1-yl)methyl]-4-substituted-2,4-dihydro-3H-1,2,4-triazole-
3-thiones (4a–h) in moderate to good yields16. These compounds
are original. All the newly synthesized etodolac 1,2,4-triazoles are
air-stable solids and soluble in DMSO at ambient temperature.
The purity of the synthesized compounds was checked by thin
layer chromatography (TLC) and microanalysis. The structures of
obtained compounds were determined on the basis of FT-IR, 1H-
NMR, 13C-NMR and HR-MS spectral data and all of the
compounds have satisfactory analyses for their proposed struc-
tures. 1H-NMR soctral results for etodolac triazoles together with
hydrogen assignments. 13C-NMR and HR-MS spectra results are
also demonstrated in Experimental Section.
The refluxing of etodolac thiosemicarbazides in aqueous
NaOH transformed into the target compounds (4a–h) was
indicated in the IR spectra by appearance of a single absorption
for NH in the region 3160–3349 cm1 and disapperance of a
comparatively strong band in the region 1674–1688 cm1 for the
carbonyl of hydrazides, indicated the formation of triazoles. The
absorption bands at 1576–1416 cm1 are due to the presence of
–C¼N– stretch of the triazole ring system. Furthermore, the
appearance of a C¼S absorption band in the region 1215–
1262 cm1 indicated that the triazoles are in their thione form.
The existence of triazoles in thione form was also indicated by the
absence of SH stretching in the characteristic region of 2550–
2600 cm124.
1H-NMR data was also in agreement with the proposed
structures of all newly synthesized etodolac triazoles. Moreover,
in the 1H-NMR spectra of etodolac triazoles, additional signals
due to the NH group were appeared in the region of  13.38–
13.82 ppm, whereas S–H proton at 1.0–3.7 ppm was not detected
which also confirmed the formation of their thionic form 25.
Triazole NH resonances were observed to be shifted to downfield
because of strong intermolecular hydrogen bonding as previously
reported26,27. 1H-NMR spectra of the etodolac thiosemicarbezides
(3a–h) showed three proton signals typical for linked to N1–N2
and N4 nitrogens in the 7.03–10.55 ppm range in our previous
study, whereas in the 1H-NMR spectra of etodolac triazoles (4a–h)
the singlet peak due to the proton of NH group appeared, which
confirmed the succesful formation of the desired triazoles. All































other aromatic and aliphatic protons for obtained compounds were
observed at expected chemical shifts and integral values.
13C-NMR spectra of compounds exhibited additional signals
due to triazole moiety at the expected chemical shift values. The
carbon of triazole, C¼S group and C¼N group had a typical
signals at about 165.49–170.05 and 149.33–150.04 ppm, respect-
ively. The peaks resonated at region of 165.49–170.05 ppm in the
13C-NMR spectra of these compounds, assigned for C¼S,
confirming thione form of triazole28. The 13C-NMR spectra of
the compounds displayed the appropriate number of resonances
that exactly assembled the number of carbon atoms. The etodolac
derivatives may occur in thione or thiol form. However, in our
case the signal of C¼S group in the 13C-NMR spectra and
disappearance of S–H proton in the 1H-NMR spectra of etodolac
triazoles (4a–h) indicated that they were existed in a solution
predominantly in thione form. The thione-thiol tautomerism was
not observed for etodolac triazoles.
High-resolution mass spectra (HR-MS) confirmed the molecu-
lar weights and empirical formulae of the compounds and
fragments, with less than 5 mmu bias between the calculated
and experimental m/z values of either the molecular or the
fragment ions. The ionization mode was electron impact (EI) for
all triazole derivatives. Etodolac triazoles gave relatively stable
molecular ion peaks in the corresponding mass spectra. In
addition, the fragmentation pattern for all compounds was
supported in the mass spectra. The fragment ion peaks especially
[MN2]+, [MHCNS]+ , [MRNCS]+ and [M S] + are the
diagnostic peaks for 1,2,4-triazoles rings24,29. IR, 1H-NMR, 13C-
NMR and mass spectral data are in agreement with the proposed
structures of all newly synthesized compounds.
Biological evaluation
Anti-cancer activity
The growth inhibition properties of the compounds selected by
NCI, USA, was performed in accordance with the protocol of
their Drug Evaluation Branch Selection, and is available online at
the DTP web site (http://www.dtp.nci.nih.gov/docs/misc/com-
mon_files/guidelines.html)18,30. The cytotoxic and/or growth
inhibitory effects of the compounds with ethyl and benzyl
substituent, 4b and 4f chosen as prototypes were tested at a
concentration of 105 M against the full panel of 60 human
tumour cell lines derived from nine neoplastic diseases. The
percentage of growth was determined spectrophotometrically and
compared against DMSO-treated controls. The one-dose assay
facilitates detection of both growth inhibition (values between 0
and 100) and lethality (values less than 0). It means that a value of
100 means no growth inhibition. A value of 40 would mean 60%
Figure 1. Synthetic route of newly synthesized componds 4a–h.































growth inhibition. A value of 0 means no net growth over the
course of the experiment. A value of -40 would mean 40%
lethality. A value of 100 means all cells are dead. Compounds
with cell lines appearing on positive side of mean graph display
high growth inhibition of the specific cancer cells. The one-dose
data will be described as a mean graph of the percent growth of
treated cells. Mean graphs were established for each effect, with
bars showing the deviation of individual tumour cell lines from
the over all mean value for all the tested cells. In the mean graph,
the centre point is the mean of the growth inhibition (GI)
percentage over all cell lines. Bars that point to the right are cell
lines where the inhibition is greater than the average, while bars
that point to the left are cell lines where the inhibition is less than
the average. Compounds with cell lines appearing on positive side
of mean graph display high growth inhibition of cancer cells of
that particular cancer. In Table 1, the results of in vitro anti-cancer
screening of 4b and 4f are summarized. Tested compounds had
moderate growth inhibition effects, which means they had not
pass the 5-dose assay. They were unable to reduce the growth of
any of the cell lines to 32% or less.
5-[(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-
yl)methyl]-4-benzyl-2,4-dihydro-3H-1,2,4-triazole-3-thione, 4f
demonstrated 46.15, 45.39, 46.49, 50.03% growth percent at
105 M on CNS cancer SNB-75, melanoma UACC-257, renal
cancer CAKI-1, prostate cancer PC-3 cancer cell lines, respect-
ively. Moreover, compound 4b had a strong cytotoxicity against
melanoma MALME-3 M and compound 4f had a strong cytotox-
icity against melanoma MALME-3 M and leukemia HL-60(TB)
cell lines. There are also several reports in the literature on
etodolac which were observed to inhibit melanoma by cycloox-
ygenase inhibitors31. Our findings indicated that 1,2,4-triazoles
derivatived from etodolac keep going on effect of melanoma.
Anti-HCV NS5B polymerase activity
Previously synthesized compounds15, of etodolac ester (Lab.
Code: SGK-196), hydrazide (Lab. Code: SGK-197) etodolac
hydrazones (Lab. Code: SGK 198-210), 4-thiazolidinones (Lab.
Code: SGK 212-214, SGK 216-221, SGK223) and newly
synthesizd compounds of etodolac triazoles (4a–h,) were
evaluated for their inhibition of hepatitis C virus NS5B RNA
dependent RNA polymerase activity32. The anti-NS5B polymer-
ase activity of the etodolac 1,2,4-triazoles (Table 2) was
investigated in vitro against recombinant NS5BCD21 1b by a
primer-dependent elongation assay as described previously20,21.
All compounds were subjected to preliminary screening at
100mM concentration and candidates displaying 50% inhibition
of NS5B polymerase activity at this concentration were further
investigated for their IC50 value. Etodolac, the parent molecule,
included in this investigation for comparison, yielded 10%
inhibition of NS5B polymerase, while its derivatives displayed
5.0–80.0% inhibition of NS5B polymerase activity at this
concentration. Of these, all 11 etodolac 4-thiazolidinones proved
to be weak NS5B polymerase inhibitors with 50% anti-NS5B
activity, while two etodolac hydrazide-hydrazones and five
etodolac triazoles appeared more promising displaying 50%
inhibition of NS5B polymerase activity. The triazoles were overall
more active than the hydrazide-hydrazones, displaying IC50
values between 14.0 and 26.0 mM, with the exception of




100 mM) IC50 (mM)
SGK196 6.4 ± 1.2
SGK197 11.4 ± 1.2
Etodolac Hydrazide-Hydrazones
SGK198 6.4 ± 1.3
SGK199 16.5 ± 1.8
SGK200 30.3 ± 0.2
SGK201 6.7 ± 1.0
SGK202 61.6 ± 0.4 58.6 ± 1.4
SGK203 3.4 ± 0.4
SGK204 9.2 ± 0.9
SGK205 8.4 ± 1.4
SGK206 7.1 ± 0.4
SGK207 3.6 ± 1.1
SGK208 20.0 ± 0.1
SGK209 53.7 ± 0.5 58.6 ± 1.4
SGK210 45.3 ± 1.1
Etodolac Triazoles
4a (SGK238) 78.9 ± 0.7 14.8 ± 1.2
4b (SGK239) 74.6 ± 1.1 21.6 ± 1.3
4c (SGK240) 69.0 ± 0.1 26.0 ± 1.3
4d (SGK241) 72.3 ± 0.4 25.4 ± 1.3
4e (SGK243) 58.2 ± 0. 40.3 ± 1.2
4f (SGK242) 3.78















Table 1. The anticancer screening data of etodolac triazoles, 4b and 4f.




inhibition % of the
most sensitive cell line
Growth percent % of
the most sensitive
cell line
4b D-753678/1 102.49 Melanoma
UACC-62
22.78 77.22











































compound 4e (IC50¼ 40.0 mM). Among these, compound 4a
(SGK 238) with IC50 value of 14.8 mM was the most active of the
etodolac triazoles. General structure and substituents of etodolac
hydrazide hydrazones and etodolac 4-thiazolidinones which were
synthesized in our previous study15 are given in Supplemental
file 2.
To evaluate the probable binding conformation of the most
potent chiral etodolac derivatives, we performed docking study
using Glide docking software. Since the structurally related
pyranoindoles have been previously shown to inhibit NS5B
activity through binding to TP-II, we performed docking calcu-
lations at TP-II site13,22. Analysis of the binding energy data for
the docked conformations of R- versus S-isomers of the most
active compound of 5-[(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-
b]indole-1-yl)methyl]-4-methyl-2,4-dihydro-3H-1,2,4-triazole-3-
thione, 4a (Glidescore for (R) ¼ 2.94 kcal/mol and for (S) ¼
4.58 kcal/mol), showed that S-isomer bind at least by 1 kcal/mol
better than their R-counterpart. The binding mode of (S)-isomer of
the etodolac derivative 4a within the TP-II of HCV NS5B
polymerase is shown in Figure 2 (please view this figure in color
mode in the online version). The sp2 hybridized nitrogen atom of
the triazolethione ring forms a water (HOH677) mediated
hydrogen bond with the backbone –NH of Tyr477
(¼N  H2O  HN–Tyr477). The pyran ring oxygen atom also
involved in water (HOH677)-mediated hydrogen bonding inter-
action with the backbone –NH of Tyr477 (O  H2O677  HN–
Tyr477). This pyran ring oxygen atom is also found at electro-
static interacting distance from the backbone –NH of Ser476
(–O  HN-Ser476, 3.58 Å). The N-methyl, the thioxo and the
–NH groups of the triazolethione ring are solvent-exposed. The
ethyl substituent on indole nucleus forms hydrophobic inter-
actions with the side chains of Leu419, Met423 and Leu497.
The indole nucleus is stabilized by hydrophobic interactions
with the side chains of Met423, Tyr477, Leu497 and Trp528.
The ethylpyran moiety is mainly stabilized by hydrophobic
contacts with the side chain of Tyr477.
The binding mode of (R)-4a was found to be completely
different and showed no key hydrogen bonding interactions with
the residues of TP-II such as Ser476 and Tyr477. Therefore
binding energy data and predicted binding conformation together
suggest that NS5B inhibitory activity of racemic 4a could be due
to S-isomer. Future study will focus on separation of each
enantiomer as well as optimization of compound 4a.
Anti-cancer activity of the etodolac triazole, 4a against
human liver cancer cells
Compound 4a, which exhibited the highest inhibitory activity
against HCV NS5B polymerase, was evaluated for its ability to
Figure 2. Glide-XP predicted binding model
of compound (S)-4a within the TP-II of HCV
NS5B polymerse. Amino acid residues are
shown as stick model with the atoms colored
as carbon – green, hydrogen – white, nitrogen
– blue oxygen – red and sulfur – yellow
whereas inhibitor is shown as ball and stick
model with the same color scheme as above
except carbon atoms are represented in
orange. Water molecules are shown as stick
model. Dotted black line indicates hydrogen
bonding interaction whereas dotted pink line
indicates potential electrostatic contact with
distances in Å (please view this figure in
color mode in the online version).
Figure 3. Percent growth inhibition graphs of compound 4a, SGK-238 on
liver cancer cell lines (Huh7, Mahlavu, HepG2, FOCUS).































inhibit the growth of liver cancer employing four prototype liver
cancer cell lines, Huh7, Mahlavu, HepG2 and FOCUS. Towards
this goal, we carried out an anti-cancer drug-screening method
based on a sulforhodamine B assay (SRB) in triplicate to
determine their IC50 values
17.
The cells were treated with increased concentration from 2.5 to
40mM of the compound 4a and incubated for 72 h. Absorbance
values were obtained and normalized to DMSO control. The
result of anti-cancer analysis of this compound is summarized in
Figure 3. However, the IC50 values were in micromolar concen-
trations with 4a against each human liver cancer cells (Table 3).
5-[(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-yl)methyl]-
4-methyl-2,4-dihydro-3H-1,2,4-triazole-3-thione, 4a displayed
the best anti-cancer activity, with IC50 value of 4.29 against
Huh7 cell line. Considering the anti-cancer activity of this
etodolac triazole on the hepatoma cell lines, we further analyzed
the cellular activity as a promising candidate anti-cancer agent.
Conclusions
In the current study, a series of novel etodolac 1,2,4-triazoles were
synthesized and evaluated for their anti-cancer activity and inhib-
ition of hepatitis C virus NS5B RNA dependent RNA polymerase
activity. After a preliminary survey, 5-[(1,8-diethyl-1,3,4,
9-tetrahydropyrano[3,4-b]indole-1-yl)methyl]-4-ethyl-2,4-dihy-
dro-3H-1,2,4-triazole-3-thione, 4b and 5-[(1,8-diethyl-1,3,4,9-
tetrahydropyrano[3,4-b]indole-1-yl)methyl]-4-benzyl-2,4-dihy-
dro-3H-1,2,4-triazole-3-thione, 4f were selected by the NCI for
anti-cancer screening. These etodolac triazoles were found to
show significant inhibition on CNS cancer SNB-75, melanoma
UACC-257, renal cancer CAKI-1, prostate cancer PC-3 cancer
cell lines. In this present study, we have also evaluated inhibition
of hepatitis C virus NS5B RNA dependent RNA polymerase
activity of etodolac derivatives. Among these, the most active
triazole, compound 4a (SGK 238), with methyl substituent
displayed IC50 values of 14.8 mM. Notably, this study reports for
the first time the anti-HCV NS5B activity of etodolac 1,2,4-
triazoles. Molecular docking and binding mode investigations
suggest that the 1,2,4-triazole scaffold may be optimized for
generating more effective analogues with improved anti-NS5B
potency. In order to analyze anti-cancer property of the active
compound 4a, anti-cancer assay was investigated on diverse
human cancer cell lines. Based on these studies, the IC50 value of
compound 4a was analyzed on hepatoma cells. We are now in the
process of synthesizing modified analogues of the lead compound
in order to generate more effective hepatitis C virus NS5B
polymerase inhibitors and candidate anti-cancer agents.
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icity, and pro-apoptosis activity of etodolac hydrazide derivatives as
anticancer agents. Arch Pharm (Weinheim) 2013;346:367–79.
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